HCW Biologics Inc.
HCWBNasdaq
$4.00
↓ -1.5%Jul 17 close · end-of-day
Price
1Y↓ -86.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$21.7M
Enterprise Value
$27.1M
P/E
—
P/S
3.3
P/B
3.8
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$6.5M
Net Income (TTM)
-$2.3M
Free Cash Flow (TTM)
—
Gross Margin
99.9%
Operating Margin
-121.6%
Net Margin
-35.0%
ROE
-39.8%
ROIC
-56.6%
Debt / Equity
1.1
Net Cash
-$5.3M
Return 1Y
-85.9%
Company profile
HCW Biologics Inc. focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. Its lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis. HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia.
- CEO
- Hing C. Wong
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 40
- Headquarters
- Florida
- Website
- hcwbiologics.com
Management & directors
- Byam RebeccaChief Financial Officer
- Wong Hing CChief Executive Officer
Roles derived from SEC Form 4 filings.
Earnings
HCWB Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$6.5M↑ +128231.7%
Diluted EPS$0.37↓ -118.8%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $4.1M | $0.00 | $6.7M | $2.8M | $2.6M | $54,232.00 |
| Gross profit | — | $0.00 | $2.6M | $560,360.00 | $959,403.00 | $10,846.00 |
| Operating income | -$5.8M | -$13.4M | -$15.1M | -$25.7M | -$29.5M | -$13.2M |
| Net income | -$5.8M | -$12.9M | -$14.9M | -$25.0M | -$30.0M | -$8.0M |
| Diluted EPS | — | -$0.69 | -$0.42 | -$0.70 | -$30.96 | -$10.63 |
| Operating cash flow | -$10.4M | -$11.0M | -$10.4M | -$22.5M | -$14.2M | -$13.4M |
| Free cash flow | -$10.6M | -$11.0M | -$20.7M | -$28.7M | -$14.5M | -$13.4M |
| Gross margin | — | — | 38.5% | 19.7% | 37.4% | 20.0% |
| Operating margin | -142.1% | — | -224.3% | -905.0% | -1147.6% | -24270.7% |
| Net margin | -141.5% | — | -221.7% | -879.5% | -1169.7% | -14677.1% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $618,854.00 | $426,423.00 | $394,803.00 | $5,065.00 | $6,550.00 | $15,606.00 | $27,011.00 | $6.5M |
| Gross profit | $180,411.00 | $85,285.00 | $78,960.00 | $1,013.00 | $1,310.00 | $3,121.00 | $5,402.00 | $6.5M |
| Operating income | -$15.1M | -$3.7M | -$3.1M | -$2.0M | -$3.5M | -$3.3M | -$4.4M | $3.2M |
| Net income | -$15.3M | -$3.9M | -$3.4M | -$2.2M | -$1.9M | -$4.6M | $719,232.00 | $3.5M |
| Diluted EPS | -$16.16 | -$4.13 | -$10.47 | -$1.97 | -$6.79 | -$2.02 | $0.15 | $0.37 |
| Operating cash flow | -$4.9M | -$2.9M | -$2.8M | -$3.5M | -$3.3M | -$3.2M | -$3.4M | -$1.6M |
| Free cash flow | -$4.9M | -$3.0M | -$2.9M | -$3.5M | -$3.3M | -$3.2M | -$3.4M | — |
| Gross margin | 29.2% | 20.0% | 20.0% | 20.0% | 20.0% | 20.0% | 20.0% | 100.5% |
| Operating margin | -2445.8% | -864.1% | -795.9% | -38811.5% | -52886.7% | -21095.3% | -16439.6% | 49.8% |
| Net margin | -2469.1% | -915.1% | -854.4% | -43373.6% | -29431.0% | -29183.2% | 2662.7% | 53.4% |
Company news
Jun 30, 2026
Jun 26, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-22 | GARRETT SCOTT T | Buy | 177,936 | $1.41 | $250,000.08 | filing |
| 2026-05-22 | Wong Hing C· Chief Executive Officer | Buy | 113,879 | $1.41 | $160,000.00 | filing |
| 2026-05-22 | Byam Rebecca· Chief Financial Officer | Buy | 14,235 | $1.41 | $20,000.18 | filing |
Latest 3 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.